Midatech Group Ltd. Company Profile

10:45 EDT 17th March 2018 | BioPortfolio

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications for a number of industry segments including life sciences, electronics and fine chemicals.

Founded in 2000, Midatech Ltd is a private company headquartered in Abingdon, Oxford, UK. In 2005, it registered its manufacturing facility – Midatech Biogune S.L. – in Bilbao, Spain, which became fully operational for cGMP standard design and manufacturing of API nanoparticles in March 2007. In 2008, Midatech Ltd further expanded with the opening of PharMida AG in Basel, Switzerland, which is responsible for clinical development of Midatech’s products.

Midatech’s biocompatible nanoparticles possess a number of unique properties that make them ideal for diagnostic and therapeutic applications. The nanoparticles are water dispersible and can be designed to diffuse freely in vivo, or to target specific cells. With a diameter of less than five nm, unbound nanoparticles are rapidly excreted by the kidneys, and thereby reduce the likelihood of non-specific in vivo accumulation. Their small size potentially enables drug delivery via different routes of administration, including parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation. Furthermore, their high-degree of stability to enzymatic digestion makes them attractive for oral administration. The nanoparticles can be designed to attaching multiple ligands to the nanoparticle surface, thereby allowing multivalent drug or multi-drug delivery on a single particle. Owing to the fact that the nanoparticles self-assemble in a single synthetic step, commercial manufacturing is straightforward, safe, scalable and low cost.

Midatech Ltd. has exclusive world-wide IP for the technology covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas as well as in other industries. It also has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles.


4 & 5 Dunmore Court
Wootton Road
OX13 6BH


Phone: +44 1235 528 022
Fax: + 44 1235 528 023

News Articles [350 Associated News Articles listed on BioPortfolio]

Midatech: The Story of a Nanoparticle Start-Up

In this exclusive interview, Fintan Walton talks to Tom Rademacher, President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company. Tom discusses Midatech's b...

Midatech revenue could jump by tenfold this year, says CEO Jim Phillips

Midatech Pharma (LON:MTPH) (NASDAQ:MTP) boss Jim Phillips says the firm could see as much as a "tenfold increase" in revenue this year. His comments came after the company upgraded forecasts and s...

Strong sales ''a good validation'' for Midatech Pharma Plc's entry into the US

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) reported a tenfold year-on-year increase in revenue in the first half of 2016. Much of the increase was down to the group's acquisition of  cancer s...

Midatech Pharma selects compound for brain cancer therapy programme

The candidate is based on Midatech's gold nanoparticle technology that targets tumour cells more precisely

New loan for Midatech promises greater profitability

Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising...

Full steam ahead at Midatech as cancer treatments edge closer to the clinic

Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy

Midatech's IND for pediatric brain cancer drug approved by FDA

The FDA approved Midatech Pharma's investigational new drug application for MTX110, which is being developed as a treatment f -More- 

Critical year ahead of drug development for Midatech Pharma

Jim Phillips, chief executive at Midatech Pharma Plc (LONMTPH, NASDAQ:MTP), updates Proactive's Andrew Scott on their three high-value, lead programmes progressing through pre-clinical and clinical ...

PubMed Articles [1828 Associated PubMed Articles listed on BioPortfolio]

Transcanalicular laser-assisted dacryocystorhinostomy with diode laser.

This article compares the efficacy of transcanalicular laser assisted dacryocystorhinostomy (TL DCR) with conventional external dacryocystorhinostomy (Ex DCR). All patients were randomly divided into ...

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Application of the Pentafluorosulfanyl Group as a Bioisosteric Replacement.

The success of fluorinated molecules in drug design has led medicinal chemists to search for new fluorine-containing substituents. A major recently developed group is the pentafluorosulfanyl group. Th...

Systemic granulomatous disease in dairy cattle during a dicyandiamide feeding trial.

Mature, in-calf, non-lactating, Friesian or Friesian-cross cows were fed dicyandiamide (DCD) at daily doses of 0.15 g/kg (Group 1; n=31), 0.45 g/kg (Group 2; n=21) and 0.75 g/kg (Group 3; n=12), as pa...

Clinical Trials [3522 Associated Clinical Trials listed on BioPortfolio]

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure

Random grouping by computer, divided into two groups, a group of rhubarb treatment group, another group for the placebo group.

Companies [1600 Associated Companies listed on BioPortfolio]

Midatech Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products w...

Midatech Group Ltd.

Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel character...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Midatech Group Ltd." on BioPortfolio

We have published hundreds of Midatech Group Ltd. news stories on BioPortfolio along with dozens of Midatech Group Ltd. Clinical Trials and PubMed Articles about Midatech Group Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Midatech Group Ltd. Companies in our database. You can also find out about relevant Midatech Group Ltd. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record